Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Escherichia coli | fused N-acetyl glucosamine-1-phosphate uridyltransferase/glucosamine-1-phosphate acetyl transferase | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Mycobacterium leprae | Probable UDP-N-acetylglucosamine pyrophosphorylase GlmU | Get druggable targets OG5_131193 | All targets in OG5_131193 |
Mycobacterium ulcerans | bifunctional N-acetylglucosamine-1-phosphate uridyltransferase/glucosamine-1-phosphate acetyltransferase | Get druggable targets OG5_131193 | All targets in OG5_131193 |
Wolbachia endosymbiont of Brugia malayi | N-acetylglucosamine-1-phosphate uridyltransferase | Get druggable targets OG5_131193 | All targets in OG5_131193 |
Mycobacterium tuberculosis | Probable UDP-N-acetylglucosamine pyrophosphorylase GlmU | Get druggable targets OG5_131193 | All targets in OG5_131193 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | p21 activated protein kinase 1 Dpak1 | 0.02 | 0.0018 | 0.002 |
Entamoeba histolytica | protein kinase, putative | 0.02 | 0.0018 | 1 |
Trichomonas vaginalis | STE family protein kinase | 0.02 | 0.0018 | 1 |
Echinococcus granulosus | p21 activated protein kinase 1 Dpak1 | 0.02 | 0.0018 | 0.002 |
Entamoeba histolytica | protein kinase, putative | 0.02 | 0.0018 | 1 |
Brugia malayi | Protein kinase domain | 0.02 | 0.0018 | 0.0018 |
Entamoeba histolytica | protein kinase, putative | 0.02 | 0.0018 | 1 |
Loa Loa (eye worm) | STE/STE20/PAKB protein kinase | 0.2295 | 1 | 1 |
Trichomonas vaginalis | STE family protein kinase | 0.02 | 0.0018 | 1 |
Echinococcus granulosus | serine:threonine protein kinase PAK 3 | 0.02 | 0.0018 | 0.002 |
Giardia lamblia | Kinase, STE STE20 | 0.02 | 0.0018 | 0.5 |
Echinococcus granulosus | serine:threonine protein kinase PAK 4 | 0.2099 | 0.9067 | 1 |
Echinococcus granulosus | serine:threonine protein kinase PAK 3 | 0.02 | 0.0018 | 0.002 |
Wolbachia endosymbiont of Brugia malayi | N-acetylglucosamine-1-phosphate uridyltransferase | 0.0684 | 0.2327 | 0.5 |
Schistosoma mansoni | protein kinase | 0.02 | 0.0018 | 1 |
Schistosoma mansoni | protein kinase | 0.02 | 0.0018 | 1 |
Echinococcus multilocularis | serine:threonine protein kinase PAK 4 | 0.2099 | 0.9067 | 1 |
Echinococcus multilocularis | serine:threonine protein kinase PAK 3 | 0.02 | 0.0018 | 0.002 |
Echinococcus multilocularis | PAK box P21 Rho binding | 0.02 | 0.0018 | 0.002 |
Echinococcus multilocularis | serine:threonine protein kinase PAK 3 | 0.02 | 0.0018 | 0.002 |
Mycobacterium tuberculosis | Probable UDP-N-acetylglucosamine pyrophosphorylase GlmU | 0.0684 | 0.2327 | 0.5 |
Mycobacterium ulcerans | bifunctional N-acetylglucosamine-1-phosphate uridyltransferase/glucosamine-1-phosphate acetyltransferase | 0.0684 | 0.2327 | 0.5 |
Trichomonas vaginalis | STE family protein kinase | 0.02 | 0.0018 | 1 |
Trichomonas vaginalis | STE family protein kinase | 0.02 | 0.0018 | 1 |
Entamoeba histolytica | p21-activated kinase | 0.02 | 0.0018 | 1 |
Entamoeba histolytica | protein kinase, putative | 0.02 | 0.0018 | 1 |
Schistosoma mansoni | protein kinase | 0.02 | 0.0018 | 1 |
Mycobacterium leprae | Probable UDP-N-acetylglucosamine pyrophosphorylase GlmU | 0.0684 | 0.2327 | 0.5 |
Trichomonas vaginalis | STE family protein kinase | 0.02 | 0.0018 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 5 | Inhibition of Escherichia coli GlmU acetyltransferase activity assessed as coenzyme A production using acetyl CoA substrate | ChEMBL. | 25544688 |
IC50 (binding) | = 10 uM | Inhibition of Escherichia coli GlmU acetyltransferase activity assessed as coenzyme A production using acetyl CoA substrate | ChEMBL. | 25544688 |
IC50 (binding) | > 200 uM | Inhibition of Streptococcus pneumoniae acetyltransferase activity of GlmU using acetyl-CoA and glucosamine-1-phosphate after 30 mins by Ellman's method | ChEMBL. | 22297115 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.